Read our expansion updates Expansion update Covid update

BioConnection announces that Lava Therapeutics (LAVA), a biotechnology company creating and developing next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer, has selected BioConnection for GMP DP manufacturing. LAVA and BioConnection now work together to improve the treatment of cancer.

LAVA develops proprietary bispecific Vγ9Vδ2 T cell engagers for selected tumor targets. The opportunity for the company is to develop potent, safe and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells.
BioConnection full fills the needs of innovative (bio)pharmaceutical companies like LAVA by offering flexible state of the art development and GMP compliant manufacturing services for sterile Drug Products, both clinical and commercial.
BioConnection is currently expanding with a new large state-of-the-art production line. This benefits LAVA as it is not only possible to produce their product for clinical purposes but also enables LAVA to scale up to commercial production in time for the market – all within the same building.

“LAVA’s differentiated T cell engager platform has the potential to target oncology settings of high unmet need, based on cutting edge Dutch science. Therefore, we were looking for a supplier offering a fast, flexible and solution-driven approach for the GMP DP manufacturing. By cooperating with BioConnection, we can start our clinical trials on time”, said Steve Hurly, CEO of LAVA. “I am looking forward to working with BioConnection to translate our γδ T cell engager platform to the clinic.”
Alexander Willemse, CEO of BioConnection adds: “We are pleased to contribute to the innovative power and success of LAVA in the clinical phase and beyond by producing clinical trial material in our FDA/EMA certified manufacturing site. We look forward to working with LAVA’s team to further develop their exciting technology.”

bioconnection

Covid-19 update BioConnection

BioConnection has taken precautions related to the global outbreak of the Covid-19 virus. To start with; we are currently in full operation and running on-schedule with regard to our planned productions. Our production department is on full strength and we have no shortages of material(s) nor do we foresee them.

For our personnel we are following the guidelines as issued by the Dutch National Institute for Public Health and the Environment, RIVM (www.rivm.nl). This means that people stay at home when they show (early) symptoms connected to Covid-19. Furthermore BioConnection employees work from home as much as possible. We avoid shaking hands and keep distance from each other. We take every precaution as advised to prevent the spread of the Covid-19 virus and will fully comply to the requests as stated and/or enforced by the authorities.

Our expansion project (expansion.bioconnection.eu) is running as planned to start GMP production in Q2 2021. We stay in close contact with our suppliers for the production equipment.

We review for Covid policy changes by the authorities on a daily base and adapt to them. If changes occur, this statement will be updated accordingly so you always have the latest information. In case you have any questions, please do not hesitate to contact us via our general number or website. Current customers of BioConnection, can contact their dedicated program manager. In case you want BioConnection to become a partner in your development or manufacturing, please contact our Business Development department via contact@bioconnection.eu.

The BioConnection Management Team.

You have Successfully Subscribed!